Hiltzik: This pharma company makes a miracle HIV drug, but is blocking access for millions of low-income people

Gilead's HIV drug lenacapavir has the potential to transform HIV treatment, but the company is preventing millions of low-income patients from accessing it. The article criticizes the pharmaceutical company for prioritizing profit over equitable distribution.